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Abstract
Background: Triple-negative (TN) breast cancer, which is defined as being negative for the
estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor
receptor 2 (HER-2), represents a subset of breast cancer with different biologic behaviour. We
investigated the clinicopathologic characteristics and prognostic indicators of lymph node-negative
TN breast cancer.
Methods: Medical records were reviewed from patients with node-negative breast cancer who
underwent curative surgery at Seoul National University Hospital between Jan. 2000 and Jun. 2003.
Clinicopathologic variables and clinical outcomes were evaluated.
Results: Among 683 patients included, 136 had TN breast cancer and 529 had non-TN breast
cancer. TN breast cancer correlated with younger age (< 35 y, p = 0.003), and higher histologic
and nuclear grade (p < 0.001). It also correlated with a molecular profile associated with biological
aggressiveness: negative for bcl-2 expression (p < 0.001), positive for the epidermal growth factor
receptor (p = 0.003), and a high level of p53 (p < 0.001) and Ki67 expression (p < 0.00). The relapse
rates during the follow-up period (median, 56.8 months) were 14.7% for TN breast cancer and
6.6% for non-TN breast cancer (p = 0.004). Relapse free survival (RFS) was significantly shorter
among patients with TN breast cancer compared with those with non-TN breast cancer (4-year
RFS rate 85.5% vs. 94.2%, respectively; p = 0.001). On multivariate analysis, young age, close
resection margin, and triple-negativity were independent predictors of shorter RFS.
Conclusion: TN breast cancer had higher relapse rate and more aggressive clinicopathologic
characteristics than non-TN in node-negative breast cancer. Thus, TN breast cancer should be
integrated into the risk factor analysis for node-negative breast cancer.
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Background
Since 2001, breast cancer has been the most common can-
cer in women in Korea [1]. While its incidence appears to
be levelling off in Western countries, after decades of
increasing, it is still high and continues to increase in cer-
tain countries where it initially had a low incidence [2].
Early detection of breast cancer and the use of aggressive
multimodal treatment have successfully resulted in a
decrease in the mortality due to the disease [2]. Prognostic
and predictive factors have been widely used in treatment
decisions [2]. These factors include: the extent of axillary
lymph node involvement, histologic grade, age of the
patient, status of hormone receptors (HRs) and human
epidermal growth factor receptor 2 (HER2), and involve-
ment of lymphatic or microvascular spaces [2]. Recent
studies suggest that breast cancer is a heterogeneous dis-
ease and patients with the same diagnostic and clinical
prognostic profile can have markedly different clinical
outcomes. Therefore, further understanding of the biol-
ogy of the disease is needed to improve treatment out-
come and reduce mortality [2]. Gene-expression profiling
has identified five subtypes of breast cancer (luminal A,
luminal B, normal breast-like, HER2-overexpression, and
basal-like), each of which have a different prognosis[3,4].
The basal-like and HER2+ subtypes have shorter relapse-
free and overall survival than the luminal tumours [3-6].
Basal-like breast cancers are often called 'triple-negative'
(TN) breast cancer, defined as estrogen receptor-negative,
progesterone receptor-negative (i.e., HR-negative), and
HER2-negative. Approximately 80% to 90% of TN pheno-
typic breast cancers are deemed to be basal-like when
appropriately tested for immunohistochemical markers
and gene expression. Moreover, there is a consistent trend
across studies confirming unfavourable clinical outcomes
associated with the TN phenotype or basal-like breast can-
cer [4-14].
Previous studies in Western countries show that TN breast
cancer has aggressive clinical and pathologic features,
including onset at a young age, advanced stage at diagno-
sis, high histologic and nuclear grade, high mitotic index,
higher frequency of unfavourable histologies, and more
distant recurrence [8,10,12,15]. In addition, evidence
indicates that the prevalence and clinical outcome of TN
breast cancer differs among races [8,15]. Bauer et al. have
reported that TN breast cancer is more prevalent among
non-Hispanic black compared with other ethnic group,
who, when affected with this subtype had the worst sur-
vival [8]. Carey et al. also reported that basal-like breast
tumours occurred at a higher prevalence among African-
American women compared with other racial group [15].
However, there are limited studies of the prevalence, char-
acteristics, and prognosis of TN breast cancer in Asian
populations. A recent study of Korean patients indicated
that the basal-like subtype, which is positive for one or
more of the basal markers and negative for HRs and Her2/
neu, was not associated with a poor prognosis. This study
also showed that the survival rate associated with the
basal-like subtype does not differ from that of other sub-
types, with the exception of the Her2/neu-overexpressing
subtype, which has the worst survival rate [16]. In con-
trast, a recent study of breast cancer patients receiving neo-
adjuvant chemotherapy showed that TN breast cancer was
associated with shorter survival than other subtypes, even
though it was associated with a higher response rate [11].
The present study was designed to investigate the clinico-
pathologic characteristics and prognostic significance of
TN breast cancer in Koreans.
Methods
Patients
Patients who were diagnosed with breast cancer and
underwent curative surgery at Seoul National University
Hospital between January 2000 and June 2003 were
included in the study. The inclusion criteria were: (1)
breast cancer with negative lymph nodes on pathological
examination; (2) available results of immunohistochem-
istry for HRs and HER2. Patients who received adjuvant
trastuzumab (n = 1) or neoadjuvant chemotherapy (n = 2)
were excluded. We retrospectively evaluated each patient's
clinicopathologic features, molecular markers and clinical
outcome. This study protocol was approved by the Insti-
tutional Review Board (IRB) of the Seoul National Univer-
sity Hospital (IRB protocol number H-0809-073-258).
Because this study was a retrospective analysis that
involved no more than minimal risk for the subjects, the
IRB approved our request for the waiver of informed con-
sent.
Pathological Examination and Immunohistochemistry
Pathological examination included the type of tumour,
the tumour stage according to the criteria established by
the 6th edition of American Joint Committee on Cancer
cancer staging manual, the presence of endovascular or
lymphatic tumour emboli, the status of the resection mar-
gin, and the histologic and nuclear grade according to the
Elston and Ellis modification of the Scarff-Bloom-Rich-
ardson grading system [17,18].
Immunohistochemistry was used to test for the expression
of the following molecular markers: the estrogen receptor
(ER), progesterone receptor (PR), HER2, p53, Ki67, bcl2
and the epidermal growth factor receptor (EGFR). The
routinely formalin-fixed, paraffin-embedded tissue blocks
were sectioned at 4-μm thickness and then used for
immunohistochemistry. Tissue sections were deparaffin-
ized in xylene, rehydrated with graded ethanol, andBMC Cancer 2008, 8:307 http://www.biomedcentral.com/1471-2407/8/307
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immersed in Tris-buffered saline. After an antigen-
retrieval process, primary antibodies were used as previ-
ously described [19]. ER, PR, HER2, p53, Ki67, bcl2 and
EGFR expressions were evaluated by the avidin-biotin
complex immunohistochemical technique [20]. The pri-
mary antibodies were supplied by Novocastra Laborato-
ries Ltd., (New Castle-Upon-Tyne, UK), for HER2, and by
the Dako Corporation (Carpinteria, CA, USA) for all of
the other markers studied. The dilution factors were as fol-
lows: ER (clone 1D5), 1:50 PR (clone PgR6361), 1:50;
HER2 (clone CB11), 1:200; p53 (clone DO-7A), 1:1200;
Ki-67 (clone MIB-1), 1:800; bcl-2 (clone 124), 1:50; and
EGFR (clone H11), 1:50. All primary antibodies were
mouse monoclonal antibodies. Biotinylated anti-mouse
antibody was used as a secondary antibody and streptavi-
din horseradish peroxidase (Zymed laboratories, San
Francisco, CA) methods were used according to the
instructions provided by the manufacturer. ER and PR
positivity was defined as the presence of 10% or more
positively stained nuclei in ten high-power fields. The
intensity of HER2 membrane staining was scored as 0, 1+,
2+ or 3+. Tumours with 3+ scores were classified as posi-
tive for HER2 overexpression, whereas tumours with 0 or
1+ scores were considered as negative. And tumours with
2+ scores were classified as undetermined [12]. EGFR
staining was considered positive if membrane staining
was observed. Ki-67 of < 20% and p53 of < 25% were con-
sidered low expression.
Statistical analysis
The comparisons of clinicopathologic variables and pat-
terns of relapse between TN breast cancer and non-TN
breast cancer were made using Pearson's χ2 test or Fisher's
exact test as appropriate. Two-sided p values of < 0.05
were considered statistically significant. The associations
between molecular markers and clinicopathologic varia-
bles, including TN breast cancer and relapse-free survival
(RFS), were analyzed by Kaplan-Meier plots and log-rank
tests. The RFS was calculated from the date of surgery to
the first detection of disease recurrence. Multivariate anal-
yses were carried out using the Cox regression model. A
significance level of 0.05 was used for covariate entry.
SPSS for Windows, version 12.0 (SPSS, Inc., Chicago, IL,
USA), was used for all statistical analyses.
Results
Patient characteristics
A total of 1135 patients were diagnosed with breast cancer
and underwent curative surgery. Of these, 683 patients
were included in the study. The demographic and clinical
characteristics of the patients are summarized in Table 1.
Four hundreds and nine patients (59.9%) were ER-posi-
tive, 273 patients (40.1%) PR-positive, 175 patients
(25.6%) HER2-positive and 123 patients (18%) HER2-
undetermined [12]. One hundred and thirty-six patients
(19.9%) were TN breast cancer identified as ER-negative,
PR-negative, and HER2-negative and 529 patients
(77.5%) were non-TN breast cancer indentified as HR-
positive or HER2-positive. We excluded 18 patients
(2.6%) classified as HRs-negative and HER2-undeter-
mined group from further analyses comparing TN breast
cancer and non-TN breast cancer. Two hundreds and
eighty-four (41.6%) patients underwent breast-conserv-
ing surgery and 237 patients among them received adju-
vant radiotherapy to the lesion. Four hundreds and
eighteen (61.2%) patients received adjuvant systemic
chemotherapy. The median duration of follow-up was
56.8 months (range, 1–89.1 months). Fifty-eight (8.5%)
patients had relapses of disease during the follow-up
period.
Clinicopathologic characteristics of TN and non-TN breast 
cancer
We compared the clinicopathologic features of TN breast
cancer with those of non-TN breast cancer (see Additional
file 1). One hundred thirty-six (19.9%) patients had TN
breast cancer and 529 (77.5%) had non-TN breast cancer.
Compared with non-TN breast cancer, TN breast cancer
correlated with younger age (below 35 years, p = 0.003),
higher histologic and nuclear grade (p < 0.001 and p <
0.001, respectively), negative staining for bcl2 expression
(p < 0.001), positive staining for EGFR (p = 0.003), and
high levels of p53 (p < 0.001) and Ki67 expression (p <
0.001) (see Additional file 1). Although more patients
with TN breast cancer had received adjuvant chemother-
apy than those with non-TN breast cancer (p < 0.001), a
greater percentage of those with TN breast cancer relapsed
during the follow-up period (14.7% vs. 6.6%, respec-
tively; p = 0.004) (see Additional file 1).
Clinicopathologic variables associated with RFS
We analyzed the association between clinicopathologic
variables and RFS. The results of univariate analyses are
summarized in Additional file 2 (see Additional file 2).
Younger age (below 35 years), breast-conserving surgery,
tumour size larger than 2 cm, the presence of endovascu-
lar or lymphatic tumour emboli, a close resection margin
(< 3 mm), ER-negativity, TN breast cancer, negative stain-
ing for bcl-2 expression, and high levels of Ki67 expres-
sion correlated with shorter RFS.
On multivariate analysis, younger age (hazard ratio,
2.880; 95% CI, 1.396 to 5.939, p = 0.004), a close resec-
tion margin within 3 mm (hazard ratio, 4.495;95% CI,
1.011 to 19.986, p = 0.048), and TN breast cancer (hazard
ratio, 2.382;95% CI, 1.351 to 4.199, p = 0.003) were inde-
pendently associated with shorter RFS (Table 2).BMC Cancer 2008, 8:307 http://www.biomedcentral.com/1471-2407/8/307
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Patterns of relapse in TN breast cancer
The 4-year RFS rates in patients with TN breast cancer and
non-TN breast cancer were 85.5% and 94.2%, respectively
(p = 0.001) (Figure 1). Eighteen patients (90.0%) with
relapsed TN breast cancer had their relapses within 3 years
after surgery, whereas 19 patients (57.3%) with relapsed
non-TN breast cancer had relapses within 3 year after sur-
gery (p = 0.007) (Figure 2). The distribution of the sites of
recurrence (distant, locoregional, or contralateral breast)
was not statistically different between TN and non-TN
breast cancer (p = 0.968). TN breast cancer patients who
were younger had shorter RFS than those without these
features (p = 0.028). Patients with TN disease also had
shorter RFS than patients who were HR-positive (p  <
0.001) or HR-negative/HER2 -positive (p = 0.384) (Figure
3).
Discussion
The molecular classification of breast cancer has revealed
the heterogeneity of the disease with respect to prognosis
and response to therapy. Among the subgroups of breast
cancer, TN breast cancer is particularly feared because it is
associated with a poor clinical outcome and it has no spe-
cific systemic treatment [10-13]. However, clinical data on
TN breast cancer in Asian populations are limited. Thus,
we investigated the clinicopathologic features and the
prognostic indicators of lymph-node negative, TN breast
cancer in Koreans.
In the present study, 19.9% (136/683) of the included
patients had TN breast cancer. Carey et al. found that the
prevalence of the TN subtype among patients with breast
cancer in US was 26.4%; among non-African American
patients with breast cancer this prevalence was 23% [15].
Table 1: Demographic and clinical characteristics












Invasive ductal carcinoma 605 (88.5)
Invasive mucinous carcinoma 23 (3.4)
Invasive papillary carcinoma 17 (2.5)
Invasive lobular carcinoma 8 (1.2)
Metaplastic carcinoma 7 (1.0)
Medullary carcinoma 5 (0.7)
Tubular carcinoma 5 (0.7)
Invasive cribiriform carcinoma 5 (0.7)
Invasive micropapillary carcinoma 3 (0.4)
Mixed invasive lobular and ductal carcinoma 3 (0.4)
Invasive apocrine carcinoma 2 (0.3)
Pathological tumor size
<2 cm 399 (58.5)





BCS, Breast conserving surgery
Table 2: Independent prognostic factors influencing relapse free 
survival (multivariate analysis)
Variables HR* 95% CI p value
Age (< 35 years) 2.880 1.396–5.939 0.004
Close resection margin < 3 mm 4.495 1.011–19.986 0.048
Triple-negative 2.382 1.351–4.199 0.003
HR, hazard ratio; CI, confidence interval.
*Adjusted for age, type of surgery, tumour size, endovascular or 
lymphatic tumour emboli, status of resection margin, triple negative 
breast cancer, bcl2, and Ki67BMC Cancer 2008, 8:307 http://www.biomedcentral.com/1471-2407/8/307
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Bauer et al. reported that in US, the prevalence of TN
breast cancer among patients with all forms of breast can-
cer was 12.4% and that this prevalence was highest among
non-Hispanic black patients with breast cancer, at 24.6%
[8]. Previous studies among Asian women have reported
more than 30% of breast cancer was the TN subtype
[11,16]. While the prevalence of TN breast cancer in our
study (19.9%) was lower than in these other studies, the
prevalence among Koreans may not actually be lower. The
lower prevalence in our study may be the result of includ-
ing only node-negative patients in combination with the
association of TN breast cancer with advanced stage and,
thus, node-positive status.
In the current study, TN breast cancer was associated with
younger age, higher histologic and nuclear grade, negative
staining for bcl-2, positive staining for EGFR, and high
levels of p53 and Ki67 expression. These characteristics
are known to be markers of biologic aggressiveness and
poor prognosis in breast cancer [18,21-25]. Our observa-
tion that TN breast cancer has a shorter RFS than non-TN
breast cancer in lymph-node negative cancer is consistent
with most other studies [8-10,12,14,19]. We also found
that TN breast cancer was an independent prognostic fac-
tor for shorter RFS. These results indicate that the progno-
sis of TN breast cancer in Korean populations does not
differ from that in Western countries.
In the current study, most of the relapses in TN breast can-
cer occurred within the first 3 years, in contrast to non-TN
breast cancer. This finding reflects the aggressiveness of
TN breast cancer and is consistent with previously
reported results, such as those from the study by Dent et
al [10]. They reported that the risk of recurrence declined
rapidly after 4 years and no recurrences occurred after 8
years. Rakha et al. reported that the only prognostic
marker among the TN breast cancer in the lymph node-
negative subgroup was the basal phenotype, defined as
the expression of CK5/6 or CK14 [9]. These results suggest
the possibility of sub-classifications of TN breast cancer
and the necessity for further study. And patients with TN
breast cancer had shorter RFS than patients who were HR-
positive or HR-negative/HER-2 positive. Considering the
high proportion of HER2-positive patients among HR-
Kaplan-Meier plot of RFS according to triple negative (TN) phenotype Figure 1
Kaplan-Meier plot of RFS according to triple negative (TN) phenotype.BMC Cancer 2008, 8:307 http://www.biomedcentral.com/1471-2407/8/307
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negative patients (39.5%) in this study and the expected
efficacy of adjuvant trastuzumab, it is reasonable to sepa-
rate TN breast cancer from HR-negative breast cancer in
planning treatment [27-29].
The current study has a number of limitations. Some
patient records lacked the results of immunohistochemi-
cal analyses for biologic markers other than HR and
HER2. The result of HER2 fluorescence in situ hybridiza-
tion in the primary tumour was not available in the
majority of patients. In the present study, HER2 0 or 1+
was classified as HER2-negative for clarifying TN breast
cancer although a previous study showed that clinical out-
come of TN breast cancer was not significantly different
whether HER2 2+ patients were classified as HER2-nega-
tive or HER2-positive [12]. Eighteen patients (14.6%) of
HR-negative patients were classified as HER2-undeter-
mined group. There is lack of consensus regarding the def-
inition of basal-like breast cancer and TN breast cancer.
However, in spite of different classifications, there is a
consistent result across all studies suggesting the aggres-
sive clinicopathologic and biologic features of TN breast
cancer and basal-like breast cancer [3-12]. Another limita-
tion is the short duration of follow-up which makes the
overall survival analysis unfeasible. In conclusion, TN
breast cancer, defined by negative HR and HER2 status,
was associated with more aggressive clinicopathologic
features and molecular markers and with shorter RFS. We
confirmed TN breast cancer was a significant prognostic
factor in lymph-node negative breast cancer in Koreans.
Thus, identifying this subtype should be integrated into
risk factor analysis for node-negative breast cancer.
Lately, some studies have reported that the phenotypical
and molecular features of BRCA1-associated breast can-
cers are sporadically shared by TN breast cancers [29-31].
These findings suggest that the defect in the DNA-repair
pathways characteristic of BRCA1-related cancers may also
occur in TN breast cancers and this molecular defect may
be more specifically targeted [32-34]. On the basis of pre-
vious data, further studies are needed to define breast can-
cer subtypes in greater detail and to develop and assess
specifically targeted therapies.
Kaplan-Meier plot of cumulative relapse rate among patients with relapses Figure 2
Kaplan-Meier plot of cumulative relapse rate among patients with relapses. TN = triple negative breast cancer.BMC Cancer 2008, 8:307 http://www.biomedcentral.com/1471-2407/8/307
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Conclusion
TN breast cancer was associated with more aggressive clin-
icopathologic features and molecular markers and with
shorter RFS. TN breast cancer was a significant prognostic
factor in lymph-node negative breast cancer in Koreans.
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